Lucie Lafay-Cousin1, Taryn Fay-McClymont1, Donna Johnston2, Chris Fryer3, Katrin Scheinemann4, Adam Fleming5, Juliette Hukin3, Laura Janzen6, Sharon Guger6, Douglas Strother1, Donald Mabbott6, Annie Huang7, Eric Bouffet7. 1. Division of Hematology Oncology Bone Marrow Transplantation, Alberta Children's Hospital, Calgary, Alberta, Canada. 2. Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada. 3. Children and Women Hospital of British Columbia, Vancouver, British Columbia, Canada. 4. Mc Master University Hospital, Hamilton, Ontario, Canada. 5. Children's Hospital of Montreal, Montreal, Quebec, Canada. 6. Department of Psychology, Hospital for Sick Children, Toronto, Ontario, Canada. 7. Pediatric Brain Tumor Program, Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Because atypical teratoid rhabdoid tumor(ATRT) is a rare disease of infancy carrying a grim prognosis, focus on long-term outcome, especially neurocognitive remained very limited. With new era of multimodality therapy, an increasing proportion of patients are now long-term survivors. PROCEDURE: Retrospective review of neuropsychological (NP) status of survivors from the Canadian ATRT registry. RESULTS: Among 77 patients diagnosed between 1995-2012, 16(22%) were survivors. Formal NP assessments were available in eight patients. Partial information on academic achievement was available on three additional patients. There were four girls and seven boys diagnosed at a median age of 27.5 months. Seven patients underwent complete resection and three had metastatic disease. All but one received sequential high dose chemotherapy. Five patients received intrathecal chemotherapy. Three patients underwent radiation. Median age at time of formal NP assessment was 7.6 years (3.9-9.8). Full Scale Intellectual Quotient (FSIQ) ranged from less than 50-119 (mean 78). Simple expressive and receptive language appeared relatively preserved. Three recently diagnosed patients (median time assessment from diagnosis 2.6 years (1.6-4.7)) had average to high average FSIQ, academic and visual spatial skills, visual, and verbal memory. Five other patients diagnosed earlier and tested at a median time of 4.9 years (3.3-8.3) post-diagnosis had a FSIQ ranging from <50 to 71. Approximately 50% of their scores were in the impaired range. CONCLUSION: Overall this cohort appears significantly impaired at school age despite the absence of systematic radiotherapy. Larger series focusing on neurocognitive outcome are needed in the current context where treatment strategies include adjuvant radiation.
BACKGROUND: Because atypical teratoid rhabdoid tumor(ATRT) is a rare disease of infancy carrying a grim prognosis, focus on long-term outcome, especially neurocognitive remained very limited. With new era of multimodality therapy, an increasing proportion of patients are now long-term survivors. PROCEDURE: Retrospective review of neuropsychological (NP) status of survivors from the Canadian ATRT registry. RESULTS: Among 77 patients diagnosed between 1995-2012, 16(22%) were survivors. Formal NP assessments were available in eight patients. Partial information on academic achievement was available on three additional patients. There were four girls and seven boys diagnosed at a median age of 27.5 months. Seven patients underwent complete resection and three had metastatic disease. All but one received sequential high dose chemotherapy. Five patients received intrathecal chemotherapy. Three patients underwent radiation. Median age at time of formal NP assessment was 7.6 years (3.9-9.8). Full Scale Intellectual Quotient (FSIQ) ranged from less than 50-119 (mean 78). Simple expressive and receptive language appeared relatively preserved. Three recently diagnosed patients (median time assessment from diagnosis 2.6 years (1.6-4.7)) had average to high average FSIQ, academic and visual spatial skills, visual, and verbal memory. Five other patients diagnosed earlier and tested at a median time of 4.9 years (3.3-8.3) post-diagnosis had a FSIQ ranging from <50 to 71. Approximately 50% of their scores were in the impaired range. CONCLUSION: Overall this cohort appears significantly impaired at school age despite the absence of systematic radiotherapy. Larger series focusing on neurocognitive outcome are needed in the current context where treatment strategies include adjuvant radiation.
Authors: Khaled Elsayad; Jan Kriz; Laith Samhouri; Uwe Haverkamp; Ronald Straeter; Walter Stummer; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2016-06-07 Impact factor: 3.621
Authors: Lindsey M Hoffman; Elizabeth Anne Richardson; Ben Ho; Ashley Margol; Alyssa Reddy; Lucie Lafay-Cousin; Susan Chi; Irene Slavc; Alexander Judkins; Martin Hasselblatt; Franck Bourdeaut; Michael C Frühwald; Rajeev Vibhakar; Eric Bouffet; Annie Huang Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300
Authors: Cassie Kline; Schuyler Stoller; Lennox Byer; David Samuel; Janine M Lupo; Melanie A Morrison; Andreas M Rauschecker; Pierre Nedelec; Walter Faig; Dena B Dubal; Heather J Fullerton; Sabine Mueller Journal: Front Oncol Date: 2022-06-23 Impact factor: 5.738
Authors: Meerim Park; Jung Woo Han; Seung Min Hahn; Jun Ah Lee; Joo-Young Kim; Sang Hoon Shin; Dong-Seok Kim; Hong In Yoon; Kyung Taek Hong; Jung Yoon Choi; Hyoung Jin Kang; Hee Young Shin; Ji Hoon Phi; Seung-Ki Kim; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Do Hoon Lim; Hyung Jin Shin; Hyery Kim; Kyung-Nam Koh; Ho Joon Im; Seung Do Ahn; Young-Shin Ra; Hee-Jo Baek; Hoon Kook; Tae-Young Jung; Hyoung Soo Choi; Chae-Yong Kim; Hyeon Jin Park; Chuhl Joo Lyu Journal: Cancer Res Treat Date: 2020-10-28 Impact factor: 4.679